S C R U B B I N G U P
Diving deep into the future of pharma , Chris Moore , President of Veeva Europe , a leader in cloud-based software for the global life sciences industry takes us through his observations on how Big Data will support personalised medicine , how top device manufacturers will stake their claim , how specialised medicines will push biopharma and more .
THE FUTURE FORCES SHAPING PHARMA
In 2023 , precision targeting for personalised medicines , improving the information flow between reps and healthcare professionals and advancements in clinical trials have driven the adoption of new technologies , but we are only at the beginning . With these advancements come more valuable data and the potential to make better-informed decisions . Using better connected data and processes will help reduce friction to speed up the delivery of treatments to the right patients , at the right time , as well as reducing cost .
In 2024 , companies will focus on making Big Data ( which could range from raw trial and site-specific data to IT data points , such as cycle times ) more usable by resolving common pain points around cleaning , ownership and standards . As a result , the volume and frequency of access to study data will increase exponentially . This will require a
As we progress through 2024 , we are set to see all these areas continue to mature and evolve . Pharma and healthcare providers who can successfully embrace data , analytics and digital platforms will be the best positioned to succeed in 2024 and beyond .
Development teams will rethink Big Data to support personalised medicine
The life sciences industry has been waiting a long time for Big Data to transform the commercial viability of personalised medicine . With automation now coming of age , R & D teams can finally seize the opportunity – as long as their data is also clean , standardised , interoperable and secure .
www . intelligenthealth . tech 67